Emerging biomarkers hold promise for better selecting patients with non–small cell lung cancer (NSCLC) who are good candidates for immune checkpoint inhibitors, according to a review published in the journal Cancer.
A diagnosis of small-cell lung cancer (SCLC) carries with it a grim prognosis. Standard therapy for extensive-stage disease, which consists of combination chemotherapy and radiation, is associated with 5-year overall survival rates of just 5%-10%.
Neutrophil-lymphocyte ratio predicts response to immunotherapy in NSCLCBY CHRISTINE KILGORE MDedge News SAN FRANCISCO – For patients with non–small cell lung cancer, the ratio of neutrophils to lymphocytes appears to be predictive of response to immune checkpoint...
Blood tumor mutational burden predicts immunotherapy outcomes in NSCLCBY CHRISTINE KILGORE MDedge News For patients with non–small cell lung cancer (NSCLC), a blood test of tumor mutational burden (TMB) could predict clinical responses to checkpoint inhibitors,...
B7-H3 stands out as future SCLC targetBY CHRISTINE KILGORE MDedge News FROM THE JOURNAL FOR IMMUNOTHERAPY OF CANCER About two out of three patients with small cell lung cancer (SCLC) express B7-H3, a B7 family ligand that may one day serve as a therapeutic target,...
Cost And Coping
Diagnosis and Therapy